MAPT and Alzheimer disease: The mechanism by which STZ induces AD is not entirely understood, but it is known that the compound can enter CNS cells via glucose transporter 2 (GLUT2) and interfere with the insulin receptor (IR), compromising the glycogen synthase kinase 3 (GSK3) pathway and affecting the metabolism of Aβ peptide and tau phosphorylation.